“Open and Collaborative” Research: A New Model for Biomedicine Arti K. Rai Professor, Duke Law School January 11, 2005

Slides:



Advertisements
Similar presentations
David M. Pollock Medical College of Georgia Discovery-Academia.
Advertisements

Complexities of Designing a Research Exemption Arti K. Rai Professor, Duke Law School.
Strategy and Project Management in the Academic Setting What best practices from industry can be applied within the academic setting?
Blurred Boundaries: Tensions Between Open Scientific Resources and Commercial Exploitation of Knowledge in Biomedical Research Iain M. Cockburn Boston.
By Joseph P. Allen 2014 AUTM Eastern Regional Meeting.
1 UMass Dartmouth Conflicts of Interest Policies UMass Dartmouth Liz Rodriguez February 17, 2011.
Personal financial benefit or economic interest from one’s position that may inappropriately: influence the employee’s judgment compromise the employee’s.
Based on Limited Experience Many many exceptions.
Technology and Economic Development Intellectual Property Issues in Research Jim Baker Director Office of Technology and Economic Development
University of Toronto Patent Colloquium:. Illustration of Sequential Innovation Processes Application 1 Application 2 Application 4 Application 5 Application.
The Bayh-Dole Act of 1980: Policy Model for Other Industrial Economies? David C. Mowery Haas School of Business U.C. Berkeley & NBER Bhaven N. Sampat University.
Intellectual Property Rights Regulations in Russia: Case of Government-Supported R&D Irina Dezhina Leading Researcher, Ph.D. Institute for the Economy.
CONFIDENTIAL © 2012 Barnes & Thornburg LLP. All Rights Reserved. This page, and all information on it, is confidential, proprietary and the property of.
Notice: The views expressed here are those of the individual authors and may not necessarily reflect the views and policies of the United States Environmental.
Strategic Use and Adaptation of Intellectual Property Rights Systems in Information and Communications Technologies-based Research comments on.
SCHOOL OF INFORMATION UNIVERSITY OF MICHIGAN Alliance for Cellular Signaling (AfCS) “Scaling up” academic science.
Public Norms and Private Ordering: The Contractual Creation of a Biomedical Research Commons Prof. Peter Lee UC Davis School of Law October 4, 2008 Prof.
Ethical Issues in Patent Law Biotechnology and Research Ethics Clinical Research: Conflicts and Controversies Patricia C. Kuszler, M.D., J.D. University.
Knowledge Translation Mechanisms Movement of highly skilled students Publication of results Professional interactions Industry sponsored research Multi-firm.
Knowledge Commons: The Case of the Biopharmaceutical Industry Arti K. Rai Duke Law School.
Open Source, Open Science Dan L. Burk University of Minnesota Law School.
IPR and Innovation Ashish Arora Heinz School, Carnegie Mellon University.
Science – industry interaction and the early careers of Swiss PhDs Christian Zellner & Stéphane Lhuillery EPFL – CdM –
Public-Private Cooperation for the Future of Genomics Cindy Fung & Miranda Ip Stanford-in-Washington "How Health & Science Policy Decisions Are Made”
Factors Fostering Academics to Start up New Ventures: an Assessment of Italian Founders' Incentives Fini R., Grimaldi R., Sobrero M. University of Bologna,
DATA PRESERVATION IN ALICE FEDERICO CARMINATI. MOTIVATION ALICE is a 150 M CHF investment by a large scientific community The ALICE data is unique and.
The National Academies’ Board on Life Sciences Dr. Frances Sharples Director National Research Council National Research Council.
Vilnius Lithuania BSc.: Biochemistry Neuropsychology J.D.: University of Oregon LL.M.:University College London Pacific Northwest National Laboratory.
Research Bioethics Consultation: More potential than sequencing genomes Benjamin S. Wilfond MD Seattle Children’s Hospital Treuman Katz Center for Pediatric.
Entrepreneurial Professors and Secrecy in Science: Variations and Impact Karen Seashore Louis University of Minnesota Eric G Campbell Harvard University.
Exploring Cross-sectoral Transfer of Regional Innovative Capacity: from agriculture biotechnology to health care Jeremy Karwandy Interdisciplinary M.Sc.
1 Life Technologies™ Proprietary | AIPLA Winter Meeting Presentation January 2013.
Safeguarding the Public Interest with NIH and EU Research Funding Sandeep P. Kishore Universities Allied for Essential Medicines Young Professionals Chronic.
Universities and Firms: A Comparative Analysis of the Interactions Between Market Process, Organizational Strategies and Governance Seminar, September.
Yann Joly (McGill University), Angus Livingstone (University of British Columbia), Edward S. Dove (McGill University) GENOME CANADA, GPS 2011 Series September.
WIPO Dispute Resolution in International Science & Technology April 25, 2005 Ann M. Hammersla Senior Counsel, Intellectual Property Massachusetts Institute.
The U.S. Federal Budget in Science and Technology Kei Koizumi April 14, 2008 for the International Seminar on Policies of Science, Technology and Innovation.
0 A Shared Path Forward for Improved Technology Transfer Matthew Riggins.
Contracting to Preserve Open Science: Lessons for a Microbial Research Commons Prof. Peter Lee UC Davis School of Law October 8, 2009
Perspectives on the Sharing of Research Materials and Data Reid Adler Founder and Principal, Practical Innovation Strategy Washington, DC Presentation.
The Economic and Social Context of US Higher Education Josef C. Brada Arizona State University 1.
Making Sense of the Social World 4 th Edition Chapter 11, Evaluation Research.
Government Funded Inventions Mark L. Rohrbaugh, Ph.D., J.D. Acting Director Office of Technology Transfer National Institutes of Health.
NIH Funding Recipient Responsibilities February, 2004 Office of Technology Transfer Office of the Director National Institutes of Health.
Identification of national S&T priority areas with respect to the promotion of innovation and economic growth: the case of Russia Alexander Sokolov State.
D.Zucker Draft-EB09 Ethics & Academic Technology Transfer: Patients, Products and Public Trust Deborah Zucker, MD, PhD, Tufts Medical Center.
Identifying the Impacts of Technology Transfer Beyond Commercialization FPTT National Meeting, June 12, 2007.
Synthetic Biology: Caught between Property Rights, the Public Domain, and the Commons Nahum Seifeselassie May 16, 2012.
Toward a new era of intellectual property: aligning competition and IP policy Richard Gold Associate Professor Innovative to abuse? Exploring the interactions.
1970s Functional Genetics From … Functional Genomics … to … Evolution of.
University Patenting: Estimating the Diminishing Breadth of Knowledge Diffusion and Consumption by Carlos Rosell and Ajay Agrawal Comments by Mark Schankerman.
Bayh-Dole: from patenting university “widgets” to promoting knowledge networks and markets Mario Cervantes Senior Economist, OECD Directorate for Science,
Social Ecological Models
Intellectual Property Right Bernard Denis, DG-KTT.
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
DOE Data Management Plan Requirements
HOW DO PATENTING AND LICENSING AFFECT RESEARCH? JOAN S. LEONARD VICE PRESIDENT AND GENERAL COUNSEL HOWARD HUGHES MEDICAL INSTITUTE The National Academies.
Health Technology Assessment
Itzhak Goldberg Jean-Louis Racine The World Bank Restructuring of Research and Development Institutes in Eastern Europe and Central Asia Knowledge Economy.
Initiatives Drive Pediatric Drug Development January 30, 2002.
Privatizing the intellectual commons: Universities and the commercialization of biotechnology Nicholas S. Argyres and Julia Porter Liebeskind Journal of.
US University Patenting and Licensing: Historical Evolution and Recent Trends David C. Mowery Haas School of Business U.C. Berkeley.
Climbing atop the Shoulders of Giants: The Impact of Institutions on Cumulative Research Furman and Stern AER 2011.
Research Tools Retold: Bayh-Dole, Research Tools, and the Scientific Enterprise David Winickoff, JD, MA Associate Professor, Bioethics and Society University.
Ownership & (intellectual) property rights in publicly funded biobanks - Challenges, Opportunities & Alternatives - 45 min Assoc. Prof. Timo Minssen.
The Academic/Industrial
Nicholas S. Argyres and Julia Porter Liebeskind
Making “Open Data” Work: Challenges for Data Integration in Genomics Research
Gilbert Nicolaon Kiev June 10, 2008
Patenting of Research Tools and Biomedical Innovation
Presentation transcript:

“Open and Collaborative” Research: A New Model for Biomedicine Arti K. Rai Professor, Duke Law School January 11, 2005

Biology Research: A Simplified History Until late 1970s, molecular biology not applicable commercially Until late 1970s, molecular biology not applicable commercially Few IPRs Few IPRs But secrecy: fierce competition among small labs for publication priority But secrecy: fierce competition among small labs for publication priority 1966: only 45% of biologists felt comfortable talking outside lab (Walsh & Hong 2003) 1966: only 45% of biologists felt comfortable talking outside lab (Walsh & Hong 2003) Higher percentage than other sciences (cf. Merton – communal production in prestige economy should lead to great openness) Higher percentage than other sciences (cf. Merton – communal production in prestige economy should lead to great openness)

The Move Towards Proprietary Rights in Research Molecular biology becomes commercially appealing Molecular biology becomes commercially appealing Bayh-Dole encourages university patenting and exclusive licensing for purposes of commercialization Bayh-Dole encourages university patenting and exclusive licensing for purposes of commercialization Court of Appeals for the Federal Circuit Court of Appeals for the Federal Circuit

University Biotechnology Patents:

Current Complaints Some broad patents, exclusive licensing Some broad patents, exclusive licensing Possible “thickets” (Heller & Eisenberg 1998) Possible “thickets” (Heller & Eisenberg 1998) Increasing secrecy? (Campbell et al. 2002) Increasing secrecy? (Campbell et al. 2002) NIH, NRC emphasize access NIH, NRC emphasize access

Beyond Access:”Open and Collaborative” Production Disavows exclusionary IPRs and focus on individual small lab Disavows exclusionary IPRs and focus on individual small lab Influenced by model of OS software (took root when CS/cyberinfrastructure migrated to biology) Influenced by model of OS software (took root when CS/cyberinfrastructure migrated to biology) Another foil: high energy physics Another foil: high energy physics

OS Production of Software: History Some roots in academic/Mertonian modes of production Some roots in academic/Mertonian modes of production But always had explicit mechanisms for information integration But always had explicit mechanisms for information integration

OS Software Now Heterogeneous: 80,000 or so projects Heterogeneous: 80,000 or so projects Most OS projects don’t occur in academic sector (intrinsic and extrinsic motivations well beyond Merton) Most OS projects don’t occur in academic sector (intrinsic and extrinsic motivations well beyond Merton) Commercial firms make profits on complementary services Commercial firms make profits on complementary services But biomedical research inspired by OS model often occurs in academia (though more hierarchy/integration than Merton) But biomedical research inspired by OS model often occurs in academia (though more hierarchy/integration than Merton)

Categories of OC Biomed Research Highly modular: open source bioinformatics software Highly modular: open source bioinformatics software Modular: genomic databases Modular: genomic databases Beyond modular information: wet labs Beyond modular information: wet labs

Empirical Project Thus Far Semi-structured interviews of scientists involved in OC work (snowball sampling) Semi-structured interviews of scientists involved in OC work (snowball sampling) Ask corresponding university tech transfer officers about projects Ask corresponding university tech transfer officers about projects Interviewing tech transfer officers of “top” biotech, software patentees and recipients of NIH funding about OS software Interviewing tech transfer officers of “top” biotech, software patentees and recipients of NIH funding about OS software

OS Software Projects (195 projects) (195 projects) Most licenses not “plain vanilla” GPL (as contrasted with 72% at Sourceforge) Most licenses not “plain vanilla” GPL (as contrasted with 72% at Sourceforge) Cf. Lerner and Tirole (the scope of Open Source) Cf. Lerner and Tirole (the scope of Open Source)

Policies of TTOs Not much software patenting by universities (Drop from 1% to 0.6% of total in period from 1980 to 2000?) Not much software patenting by universities (Drop from 1% to 0.6% of total in period from 1980 to 2000?) Cultural differences: software vs. biology Cultural differences: software vs. biology Some TTOs in midst of formulating policy Some TTOs in midst of formulating policy Others in “don’t ask, don’t tell” mode Others in “don’t ask, don’t tell” mode MIT, Stanford, UT report deference to researchers MIT, Stanford, UT report deference to researchers Cf. University of Washington, Georgia State Cf. University of Washington, Georgia State

Genomic Databases Human Genome Database paves way (copyleft vs. public domain) Human Genome Database paves way (copyleft vs. public domain) Better sequencing machines improve modularity Better sequencing machines improve modularity Feb. 2003: principles extended to all genome sequencing projects Feb. 2003: principles extended to all genome sequencing projects Collaborative improvement through DAS Collaborative improvement through DAS Policy imposed on TTOs Policy imposed on TTOs

International HapMap Project Aims to catalogue patterns of genotypic variation (“haplotypes”) Aims to catalogue patterns of genotypic variation (“haplotypes”) Achieve association of haplotypes with complex disease Achieve association of haplotypes with complex disease HapMap Data Access Policy: copyleft model (until recently) HapMap Data Access Policy: copyleft model (until recently) Until haplotypes determined and released, access to individual genotype information conditioned on not using it to seek patents on haplotypes Until haplotypes determined and released, access to individual genotype information conditioned on not using it to seek patents on haplotypes

“Wet Lab” Biology Work often not modular (in case of AFCS, “vast uncharted territory”) Work often not modular (in case of AFCS, “vast uncharted territory”) Harder to see translation Harder to see translation

AFCS 8 labs: 7 “wet labs,” 1 bioinformatics lab 8 labs: 7 “wet labs,” 1 bioinformatics lab “High-throughput” analysis of how cells respond to different chemicals “High-throughput” analysis of how cells respond to different chemicals Labs use same inputs, analyze different types of outputs Labs use same inputs, analyze different types of outputs Much work has gone into standardization of inputs Much work has gone into standardization of inputs But work is still highly interdependent But work is still highly interdependent

IPRs and Publication Al Gilman required disavowal of all IPRs Al Gilman required disavowal of all IPRs Reluctance on part of participating TTOs Reluctance on part of participating TTOs Research reports published on Web after limited peer review Research reports published on Web after limited peer review

Evaluation: Software Arguments for and against OS software (and public funding thereof) Arguments for and against OS software (and public funding thereof) WMEABAS and transaction costs WMEABAS and transaction costs But modularity itself should reduce such costs somewhat (markets for technology) But modularity itself should reduce such costs somewhat (markets for technology) Need for viral licensing unclear Need for viral licensing unclear Universities won’t get involved unless lots of consulting revenues Universities won’t get involved unless lots of consulting revenues

Evaluation: Databases Need for some (significant?) public funding to create database Need for some (significant?) public funding to create database Agency pressure needed Agency pressure needed DAS and transaction cost reduction? DAS and transaction cost reduction? Transaction cost reduction for downstream players (e.g. pharma)? Transaction cost reduction for downstream players (e.g. pharma)? Viral licensing could be problematic Viral licensing could be problematic Shows need for research exemption? Shows need for research exemption?

Evaluation: Wet Lab Very significant coordination, funding needed; limits on number of participants Very significant coordination, funding needed; limits on number of participants But systems biology probably require resources of more than one small lab But systems biology probably require resources of more than one small lab Lack of systems biology knowledge may be why drugs are failing Lack of systems biology knowledge may be why drugs are failing Disavowal of future IPRs may substantially reduce transaction costs for collaborations in inchoate areas Disavowal of future IPRs may substantially reduce transaction costs for collaborations in inchoate areas

Transaction Cost Problems Complex non-disclosure agreements to prevent information leakage Complex non-disclosure agreements to prevent information leakage Arguments about ownership of future discoveries in inchoate areas Arguments about ownership of future discoveries in inchoate areas Default ownership rules in patent area unattractive Default ownership rules in patent area unattractive But default rules “information forcing,” avoid anticommons; changes could be problematic But default rules “information forcing,” avoid anticommons; changes could be problematic AFCS vs. Cell Migration Consortium AFCS vs. Cell Migration Consortium

Viral Licensing, Incentives, and IPRs Viral licensing could be very problematic Viral licensing could be very problematic Insufficient incentives for young data generators? Insufficient incentives for young data generators? Move towards conventional publication? Move towards conventional publication? Should be able to publish based on publicly available data Should be able to publish based on publicly available data Long-term: publish first, peer review later? (arXiv.org model) Long-term: publish first, peer review later? (arXiv.org model) Very hard to get universities to disavow IPRs Very hard to get universities to disavow IPRs

Conclusion For modular information, OC may reduce transaction costs to some extent For modular information, OC may reduce transaction costs to some extent For “inchoate” wet lab biology, OC may substantially reduce such costs For “inchoate” wet lab biology, OC may substantially reduce such costs Institutional obstacles in both cases (greater in latter case) Institutional obstacles in both cases (greater in latter case)